The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prolaris: A novel genetic test for prostate cancer prognosis.
Michael K. Brawer
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Jack M. Cuzick
Honoraria - Myriad Genetics
Research Funding - Myriad Genetics
Matthew R. Cooperberg
Consultant or Advisory Role - Myriad Genetics
Gregory P. Swanson
Other Remuneration - Myriad Genetics
Stephen J. Freedland
No relevant relationships to disclose
Julia E. Reid
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Gabrielle Fisher
No relevant relationships to disclose
Jerry S. Lanchbury
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Alexander Gutin
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Steven Stone
Employment or Leadership Position - Myriad Genetics
Stock Ownership - Myriad Genetics
Peter Carroll
No relevant relationships to disclose